Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 350-358

  Yosifov, Deyan Y ^a,b   Konstantinov, Spiro M ^a,b   Berger, Martin R ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alkylphosphocholines; Caspase activation; Cell free system for apoptosis; Cytotoxicity; Erufosine; Multiple myeloma; PARP cleavage; Programmed cell death

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL STRUCTURE; CHROMATIN CONDENSATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; NITROBLUE TETRAZOLIUM TEST; TUMOR CELL LINE;

EID: 69149097361     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04694.x     Document Type: Conference Paper

References (28)

1. Parkin, D.M. et al. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55 : 74 108.
2. Piazza, F.A. et al. 2007. Towards a new age in the treatment of multiple myeloma. Ann. Hematol. 86 : 159 172.
3. Katzel, J.A., P. Hari D.H. Vesole. 2007. Multiple myeloma: charging toward a bright future. CA Cancer J. Clin. 57 : 301 318.
4. Ludwig, H. et al. 2007. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann. Oncol. 18 (Suppl 9 ix64 ix70.
5. Merchionne, F., F. Perosa F. Dammacco. 2007. New therapies in multiple myeloma. Clin. Exp. Med. 7 : 83 97.
6. Gajate, C. F. Mollinedo. 2007. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109 : 711 719.
7. Eibl, H. J. Engel. 1992. Synthesis of hexadecylphosphocholine (miltefosine). Prog. Exp. Tumor Res. 34 : 1 5.
8. Konstantinov, S.M. et al. 1998. Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer 77 : 778 786.
9. Konstantinov, S.M. et al. 2002. Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines. Mol. Cancer Ther. 1 : 877 884.
10. Stekar, J., P. Hilgard T. Klenner. 1995. Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur. J. Cancer 31A : 372 374.
11. Catley, L. et al. 2007. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp. Hematol. 35 : 1038 1046.
12. Konstantinov, S.M., H. Eibl M.R. Berger. 1999. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol. 107 : 365 380.
13. Georgieva, M.C. et al. 2002. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett. 182 : 163 174.
14. Zaharieva, M.M. et al. 2007. Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects. Ann. N.Y. Acad. Sci. 1095 : 182 192.
15. Lucas, L. et al. 2001. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene 20 : 1110 1117.
16. Berger, M.R. et al. 2003. Induction of apoptosis by erucylphospho-N,N,N- trimethylammonium is associated with changes in signal molecule expressionand location. Ann. N.Y. Acad. Sci. 1010 : 307 310.
17. Matzke, A., U. Massing H.F. Krug. 2001. Killing tumour cells by alkylphosphocholines: evidence for involvement of CD95. Eur. J. Cell Biol. 80 : 1 10.
18. Oberle, C., U. Massing H.F. Krug. 2005. On the mechanism of alkylphosphocholine (APC)-induced apoptosis in tumour cells. Biol. Chem. 386 : 237 245.
19. Hideshima, T. et al. 2006. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 : 4053 4062.
20. Hideshima, T. et al. 2007. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br. J. Haematol. 138 : 783 791.
21. Jendrossek, V. et al. 2002. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother. Pharmacol. 50 : 71 79.
22. Fiegl, M. et al. 2007. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol. 62 : 321 329.
23. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 : 55 63.
24. Alaikov, T. et al. 2007. Antineoplastic and anticlastogenic properties of curcumin. Ann. N.Y. Acad. Sci. 1095 : 355 370.
25. Handrick, R. et al. 2005. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation. Biochem. Pharmacol. 70 : 837 850.
26. Soldani, C. A.I. Scovassi. 2002. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7 : 321 328.
27. Casiano, C.A., R.L. Ochs E.M. Tan. 1998. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ. 5 : 183 190.
28. Gobeil, S. et al. 2001. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ. 8 : 588 594.